Samik Pharm jumps 16% on monthly thymosin alpha 1 patent
The Korean drugmaker's shares rose after securing a patent for a once-a-month formulation.
TR
By Tom Reyes · Markets Editor
Sep 14 02:55 ETSource: Seoul Economic Daily
The wire
- 01Samik Pharm shares gained 16% following a patent for once-monthly thymosin alpha 1.
- 02Long-acting peptide formulations can extend product life and dosing convenience.
- 03Development stage and commercialization plans were not disclosed.
From the source
Read at news.google.comSamik Pharm Surges 16% on Once-a-Month Thymosin Alpha 1 Patent